HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species-Reference-Cited by-同舟云学术

HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species

Published:2019-10 Issue:601 Volume:12 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Nicholson Hilary E.¹^ORCID,Tariq Zeshan¹,Housden Benjamin E.²,Jennings Rebecca B.¹³^ORCID,Stransky Laura A.¹,Perrimon Norbert²⁴^ORCID,Signoretti Sabina¹³^ORCID,Harris Isaac S.⁵,Endress Jennifer E.⁵,Kaelin William G.¹⁴^ORCID

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

2. Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.

3. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

4. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

5. Ludwig Cancer Center and Harvard Medical School, Boston, MA 02115, USA.

Abstract

Blocking the kinases CDK4 and CDK6 may be a more broadly applicable therapy for patients with ccRCC.

Funder

Howard Hughes Medical Institute

National Cancer Institute

National Institute of General Medical Sciences

Peloton Therapeutics

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference45 articles.

1. World Cancer Research Fund Kidney Cancer Statistics ; www.wcrf.org.

2. Cancer statistics, 2018

3. VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

4. W. G. Kaelin Jr. Molecular biology of kidney cancer in Kidney Cancer Principles and Practice P. N. Lara E. Jonasch Eds. (Springer International Publishing ed. 2 2015).

5. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING;2024-09-06

2. Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors;Molecular Oncology;2024-08-11

3. Renal cancer: signaling pathways and advances in targeted therapies;MedComm;2024-08

4. The Janus face of HIF-1α in ischemic stroke and the possible associated pathways;Neurochemistry International;2024-07

5. Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma;Nature Reviews Urology;2024-05-02